Use, access, and initial outcomes of off-label ivosidenib in patients with IDH1 mutant glioma.

Katherine B PetersCandice AlfordAmy HeltemesAlicia SavelliDaniel B LandiGloria BroadwaterAnnick DesjardinsMargaret O JohnsonJustin T LowMustafa KhasrawDavid M AshleyHenry S FriedmanMallika P Patel

Published in: Neuro-oncology practice (2023)

Targeted therapies like IVO are options for mIDH glioma patients and can provide positive oncologic and neurological outcomes.

Keyphrases